Screening and Early Diagnosis of Hepatocellular Cancer and Optimization of Diagnostic Imaging Techniques: A Review and Conclusion of the Expert Panel by V. V. Breder, R. B. Alikhanov, S. S. Bagnenko, E. N. Bessonova, V. A. Isakov, N. E. Kudashkin, B. M. Medvedeva, A. V. Mishchenko, M. S. Novruzbekov, V. S.  Rudakov

“…Screening for HCC in high-risk groups (cirrhosis of any etiology, patients with chronic viral hepatitis B and patients with F3 liver fibrosis) should be organized as regular (every 6 months) liver ultrasound in combination with determination of the serum alpha-fetoprotein (AFP) level. …”
Get full text

Principles of effective out-patient diagnostics of diffuse liver diseases by Komova A. G., M. V. Mayevskaya, V. T. Ivashkin

“…Prevalence of diffuse liver diseases in the studied sample (n=4768) was following: non-alcoholic fatty liver disease —7,4% (n=352), alcohol-induced liver disease — 6,9% (n=329), hepatitis C — 6,7% (n=322), hepatitis B — 1,9% (n=91), drug-induced liver disease — 0,82% (n=39), cholestatic liver diseases — 0,69 % (n=33), autoimmune hepatitis — 0,78% (n=37), others — 5,4% (n=258). …”
Get full text

Human Papillomavirus, Human Immunodeficiency Virus, and Oral Microbiota Interplay in Nigerian Youth (HOMINY): A Prospective Cohort Study Protocol by Jia Liu, Esosa Osagie, Paul Akhigbe, Nosakhare Idemudia, Ozoemene Obuekwe, Ruxton Adebiyi, Nicolas Schlecht, Yana Bromberg, Fidelis E Eki-Udoko, Nosayaba Osazuwa-Peters, Modupe Oluseun Coker

“…Blood samples are tested for HIV, Hepatitis B virus (HBV) and Hepatitis C virus (HCV), with CD4, CD8 and full blood counts performed. …”
Get full text

Hepatocellular carcinoma: signaling pathways and therapeutic advances by Jiaojiao Zheng, Siying Wang, Lei Xia, Zhen Sun, Kui Ming Chan, René Bernards, Wenxin Qin, Jinhong Chen, Qiang Xia, Haojie Jin

“…Hepatocellular carcinoma (HCC) constitutes around 90% of liver cancer cases and is primarily linked to factors incluidng aflatoxin, hepatitis B (HBV) and C (HCV), and metabolic disorders. …”
Get full text

Defining indicators for disease burden, health outcomes, policies and barriers and facilitators to health services for migrant populations in the Middle East and North African regi... by Charles Agyemang, Ali Ardalan, Farah Seedat, Bouchra Assarag, Nuria Casamitjana, Kolitha Wickramage, Sally Hargreaves, Ana Requena-Mendez, Fouad M Fouad, Dominik Zenner, Anna Deal, Stella Evangelidou, Wafa Saidi, Chiaki Ito, Oumnia Bouaddi, Moudrick Abdellatifi, Alba Cuxart-Graell, Hassan Edries, Eman Elafef, Taha Maatoug, Anissa Ouahchi, Liv Mathilde Pampiri, Sara Arias, Adel Abdelkhalek, Ahmed Hamed Arisha, Ibrahim Ahmed Bani, Aasmaa Chaoui, Wafa Chemao-Elfihri, Kenza Hassouni, Mahmoud Hilali, Mohamed Khalis, Wejdene Mansour, Ali Mtiraoui, MENA Migrant Health Working Group, Asad Adam, Adnene Ben Haj Aissa, Salma Altyib, Hanen Ben Belgacem, Imane Belkhammar, Thomas Calvot, Luciana Ceretti, Nelly Chavassieux, Hassan Chrifi, Mohamed Douagi, Algdail Elnil, Gonzalo Fanjul, Ahmed Hamed, Abdedayem Khelifi, Lora Makhlouf, Maissa Mokni, Davide Olchini, Tarik Oufkir, Nasong Park, Giuseppe Raffa, Sandra Santafé, Alice Sironi, Fatma Temimi, Zeineb Turki

“…This protocol describes a suite of seven systematic reviews that aim to identify, appraise and synthesise the available evidence on the burden and health outcomes, policies and access (barriers and facilitators) related to these mobile populations in the region.Methods Seven systematic reviews will cover three questions to explore the: (1) burden and health outcomes, (2) policies and (3) healthcare barriers and facilitators for the following seven disease areas in migrants in the MENA region: tuberculosis, HIV and hepatitis B and C, malaria and neglected tropical diseases, diabetes, mental health, maternal and neonatal health, and vaccine-preventable diseases. …”
Get full text